Secura Bio

Secura Bio

Commercializes oncology therapies and develops COPIKTRA

Overview

Secura Bio is an integrated biopharmaceutical company focused on bringing oncology therapies to patients. Its main product is COPIKTRA (duvelisib), an oral PI3K inhibitor used to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The company is also running a Phase 3 study of COPIKTRA for relapsed or refractory nodal T-follicular helper cell lymphoma. Secura Bio’s approach centers on acquiring, developing, and commercializing approved and late-stage oncology assets, with headquarters in Las Vegas and a European office in Dublin. In simple terms, the company buys or develops cancer drugs and then brings them to doctors and patients who need them. Its goal is to close the gap between available oncology therapies and the patients who can benefit from them.

About Secura Bio

Simplify's Rating
Not yet rated

We're working on gathering enough insights on this company, check back soon!

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$55M

Headquarters

Mesa, Arizona

Founded

2019

Get referred to Secura Bio

See people who can refer or advise you

Funding

Total Funding

$55M

Above

Industry Average

Funded Over

1 Rounds

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-1%

2 year growth

-3%
Secura Bio
Feb 11th, 2026
Secura Bio expands Chief Financial Officer Will Brown's leadership role to include Chief Operating Officer.

Secura Bio expands Chief Financial Officer Will Brown's leadership role to include Chief Operating Officer. BERKELEY HEIGHTS, NJ, February 11, 2026 (GLOBE NEWSWIRE) - Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will Brown, currently serving as Chief Financial Officer, has been appointed to the additional role of Chief Operating Officer. In this expanded capacity, Mr. Brown will oversee daily operations, ensuring alignment with the company's strategic goals, while continuing to lead Secura Bio's financial operations and strategic planning. "Will has been instrumental in shaping our financial foundation and driving operational rigor with his extensive knowledge of the biopharmaceutical industry and deep understanding of our business," said Chip Romp, Chief Executive Officer of Secura Bio. "Expanding Will's role to include additional responsibilities as COO is a natural move for us given his exceptional leadership. Will's strategic perspective and insights will be essential to Secura Bio as we continue to embark on our bold vision to change outcomes in human health by expanding the potential of oncology medicines." Mr. Brown added, "Secura Bio is well positioned to scale and grow, and I'm excited by our long-term prospects to commercialize transformative therapies for patients while building substantial value for shareholders. I'm honored to work with such an incredible team and am inspired by the shared commitment and focus brought to work each day as we focus on our strategic initiatives to build a world-class biopharmaceutical company." Mr. Brown joined Secura Bio as Chief Financial Officer in 2024. Prior to Secura Bio, Mr. Brown served as Chief Financial Officer and Interim Chief Executive Officer at ObsEva SA, where he successfully led the company through a restructuring that generated a strategic disposition of over $100 million. Prior to ObsEva SA, Mr. Brown served as the Chief Financial Officer of Altimmune, Inc., where he was critical in the transformation and growth of the company, guiding them through more than $300 million in new equity issuances and a strategic acquisition. Prior to his pharmaceutical industry roles, Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs. Mr. Brown earned both his MBA and BS in accounting from Auburn University Montgomery. About Secura Bio, Inc. Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians and their patients. For more information on Secura Bio, please visit https://www.securabio.com/. Investor & Media Contact Will Brown CFO & COO Phone: 334-313-2319 [email protected] Media Contact Kit Rodophele Ten Bridge Communications Phone: 617-999-9620 [email protected]

Recently Posted Jobs

Sign up to get curated job recommendations

Secura Bio is Hiring for 5 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →